Generating evidence to inform policy and practice: the example of the second generation "atypical" antipsychotics.

Journal article

The introduction of the second generation "atypical" antipsychotics has been heralded as a major advance in the treatment of schizophrenia and other psychotic disorders. Systematic reviews have revealed only modest advantages over conventional antipsychotics and uncertainty about long-term efficacy and safety, yet the second generation antipsychotic drugs have been widely accepted into clinical practice. Although the existing evidence of the benefits and harms of atypical antipsychotics can f...

Expand abstract

Authors: Geddes, J

• Publication status: Published
• Journal: Schizophrenia bulletin
• Volume: 29
• Issue: 1
• Pages: 105-114
• Publication date: 2003-01-01
• DOI: 10.1093/oxfordjournals.schbul.a006980
• EISSN: 1745-1701
• ISSN: 0586-7614
• Language: English
• Keywords: Evidence-Based Medicine; Health Policy; Schizophrenia; United States; Antipsychotic Agents; Information Dissemination; Informed Consent; Randomized Controlled Trials as Topic; Humans; Guidelines as Topic